

Lords Mark Industries Takes Indian Innovation to the World Stage

In just over two decades, Lords Mark Industries Ltd. (LMIL) has grown from a modest venture into one of India's most ambitious diversified business groups, a company that today sits at the intersection of science, technology, and social impact. A global presence across MedTech, diagnostics and, biotechnology, LMIL is reshaping not only the Indian business landscape but also how the world views Indian innovation.

Healthcare lies at the heart of this transformation. LMIL's portfolio includes Renalix, the world's No.1 AI-based indigenous smart tech-enabled kidney care ecosystem, which makes early detection and dialysis accessible to rural communities, and One DNA, a genomic testing platform that puts preventive healthcare into the hands of ordinary people. The collaboration between IIT-B and Lords Mark Industries aims to revolutionize sickle cell testing in India, providing improved disease diagnosis and management for patients across the country at the point of primary care, thereby reducing costs and enabling convenience for the affected population.

Together, they reflect the company's philosophy: healthcare should be affordable, accurate, and accessible, whether in a metropolitan hospital or a small village clinic.

That focus is now driving LMIL's boldest ambitions yet. By 2027, the group plans to establish Asia's largest biochemistry plant, followed a year later by the continent's largest medical device manufacturing facility. These mega-projects will power advanced research, mass production, and exports on a scale that could place India at the center of the global MedTech map. To fund this expansion, LMIL is preparing to raise capital from global sources and is exploring a dual listing on NASDAQ and the Bombay Stock Exchange (BSE), signalling its determination to attract international partners and investors.

The company's rise is also drawing global attention. Last month, LMIL was honored at the Indo-European Business Forum (IEBF) at the House of Lords, Westminster in London for its pioneering contributions to MedTech, diagnostics, and biochemistry innovation. Political leaders, businesspeople and industry stalwarts hailed LMIL as "a shining example of how Indian enterprises can merge innovation, scale, and social impact." The summit saw participation from an illustrious gathering, including Lord David Evans, Minister Kanishka Narayan, Minister Seema Malhotra, Virender Sharma ji, His Excellency Samuel Mahama from Ghana, Dr Rohitga Sri Lanka's former Foreign Minister and High Commissioner, Dr. Neerja Birla, Niharika Handa ji, Tejesh Kumar Kodali, Subodh Kumar Gupta, Sandip Sali ji, and distinguished guests from the USA, Dubai, Hong Kong, Africa, and Europe.

"This recognition is both a validation and a responsibility," said Subodh Gupta, CEO of Lord's Mark Microbiotech, a subsidiary of LMIL. "Through Renalix and One DNA, backed by Asia's largest upcoming facilities, we are shaping the future of healthcare while delivering on India's vision of 'Make in India' and *Atmanirbhar Bharat* (self-reliant India)."



Dr. Sachidanad Upadhyay
MD and CEO,
Lords Mark Industries Ltd.



Looking ahead, the road is ambitious, and LMIL's trajectory under its young and dynamic Managing Director and CEO Sachidanand Upadhyay has demonstrated that the company is comfortable with reinvention. From its early experiments in solar and LED to its current healthcare mega projects, it has proven that Indian enterprises can not only dream big but execute with impact. As it prepares to take its innovations global, Lords Mark Industries is making a larger point: the future of healthcare will not just be built in labs and factories, but in the ability to blend scale with empathy, and ambition with responsibility.